300158 Shanxi Zhendong Pharmaceutical
- 5.02
- -0.12-2.33%
Shanxi Zhendong Pharmaceutical News
Zhendong Pharmaceutical (300158.SZ) has repurchased 2.16% of its shares at a total cost of 103 million yuan
Zhendong Pharmaceutical (300158.SZ) announced that the company's repurchase has been completed. As of April 30, 2024, the company had repurchased a total of 22.174,900 shares of the company's shares, accounting for 2.16% of the company's total share capital, and the total transaction amount was 103 million yuan (excluding transaction fees).
Zhendong Pharmaceutical (300158.SZ) appoints Liu Yongsen as financial director
Zhendong Pharmaceutical (300158.SZ) announced that the company's board of directors recently received the written resignation of Liu Changlu, the company's financial director...
Zhendong Pharmaceutical (300158.SZ): Net profit of 23.1016 million yuan for the first quarter reversed year-on-year losses
Gelonghui, April 22 | Zhendong Pharmaceutical (300158.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 782 million yuan, down 17.79% year on year; net profit attributable to shareholders of listed companies was 23.1016 million yuan, turning a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 8.5924 million yuan; basic earnings per share.
Zhendong Pharmaceutical (300158.SZ) elects director Li Kun as chairman
Zhendong Pharmaceutical (300158.SZ) announced that the company's board of directors recently received a written resignation report from the company's chairman Li Anping...
Several major problems with equity pledges and capital occupation of Zhendong Pharmaceutical have come to light
“Investor Network” Cai Jun Recently, Zhendong Pharmaceutical (hereinafter referred to as the “Company”, 300158.SZ) announced that shareholders pledged shares, involving both the controlling party and the actual controller. Earlier, the company owned Landy Pharmaceuticals and relied on it to obtain a double harvest of capital and performance. However, since 2022, the company has been in losses, and when to turn losses into profits has become a topic of concern for the market. If you want to make a profit, you need revenue side growth and cost segment control. At the same time, various transactions between the holding party and the company have also received attention from the supervisory authorities. According to the announcement, Zhendong Group, the controlling shareholder of the company, and Li Anping, the actual controller, pledged a total of 305 million shares, accounting for the public
Zhendong Pharmaceutical (300158.SZ): A total cost of 46.72 million yuan to buy back 1.02% of the shares
Gelonghui, Feb. 23 | Zhendong Pharmaceutical (300158.SZ) announced that as of February 21, 2024, the company had repurchased a total of 10,497,004 shares of the company through a special stock repurchase securities account, accounting for 1.02% of the company's total share capital. The highest transaction price was 4.81 yuan/share, the minimum transaction price was 4.31 yuan/share, and the total transaction amount was RMB 46,724,627.55.
Zhendong Pharmaceutical (300158.SZ): Initial repurchase of 8.6463 million shares involving 38.675 million yuan
Gelonghui, Feb. 7, Zhendong Pharmaceutical (300158.SZ) announced that on February 7, 2024, for the first time, the company repurchased 86463.04 million shares through a special stock repurchase securities account, accounting for 0.84% of the company's total share capital. The highest transaction price was 4.54 yuan/share, the lowest transaction price was 4.31 yuan/share, and the total transaction amount was RMB 38.27,500 (not including transaction fees).
Express News | Nearly 20 listed companies announced plans with a maximum repurchase amount of 200 million yuan after the market, and Tiger Pharmaceuticals plans to buy back 5-10 billion yuan
Express News | Zhendong Pharmaceutical: Plans to repurchase shares for 100 million yuan to 200 million yuan
A-share changes丨Zhendong Pharmaceutical fell for 5 consecutive days with an annual forecast loss of more than 30 million
Gelonghui, January 22 | Zhendong Pharmaceutical (300158.SZ) continued to fall by more than 7%, falling more than 20% for 5 consecutive days. It now reports a new low of 5.24 yuan, with a total market value of 5.4 billion yuan. The company expects a net loss attributable to shareholders of listed companies of 30 million yuan to 40 million yuan in 2023, a decrease of 22.01%-41.51% over the same period last year. During the reporting period, sales and prices of some of the company's products declined due to industry policies such as medical insurance fee control and national procurement.
Zhendong Pharmaceutical (300158.SZ) announced a net loss of 30 million to 40 million yuan in 2023, which narrowed 22% to 42% year-on-year
Zhendong Pharmaceutical (300158.SZ) disclosed its 2023 annual results forecast. The company expects the reporting period to be listed...
Zhendong Pharmaceutical (300158.SZ): To invest in Longchuangji Pharmaceutical, it will hold 60% of its shares
Gelonghui, January 19, 丨 Zhendong Pharmaceutical (300158.SZ) announced that in order to lay out the vaginal probiotics field, enrich the company's product pipeline, and enhance the company's profitability, the company signed an “Investment Agreement on Guangdong Longchuangji Pharmaceutical Co., Ltd.” (hereinafter referred to as the “Investment Agreement”) and “Equity Transfer Agreement for Guangdong Longchuangji Pharmaceutical Co., Ltd.” (hereinafter referred to as the “Equity Transfer Agreement”) with Guangdong Longchuangji Pharmaceutical Co., Ltd. (hereinafter referred to as the “Equity Transfer Agreement”) on January 19, 2024 The main content of the investment agreement is: the company to Longchuangji Pharmaceutical increased its capital by 3,0
Zhendong Pharmaceutical (300158.SZ): The company has not actually invested in Aloe Vera Qingwang and no longer holds its shares
Glonghui December 20 | Zhendong Pharmaceutical (300158.SZ) stated on the investor interactive platform on December 20 that the company has not actually invested in Aloe Vera Qingwang and no longer holds its shares.
Zhendong Pharmaceutical (300158.SZ): Phase III Employee Stock Ownership Plan Completes Stock Purchase
Gelonghui Pharmaceutical (300158.SZ) announced on December 4|Zhendong Pharmaceutical (300158.SZ) announced that as of the disclosure date of this announcement, the company's third phase of the employee stock ownership plan had purchased a total of 38,967,619 shares through centralized bidding transactions through the secondary market, accounting for 3.7925% of the company's total share capital. The total transaction amount was 244,032,009.55 yuan, and the average transaction price was about 6.2624 yuan/share.
The concept of anti-virus fluctuated and strengthened, and Tonghua Jinma rose and stopped
Gelonghui December 4 | Tonghua Jinma rose and stopped, Zhendong Pharmaceutical surged more than 10%, and Sihuan Biotech, Guangdong Wannianqing, and Shanghai Kaibao followed suit. According to the news, National Health Commission spokesman Mi Feng explained that according to surveillance, the acute respiratory diseases currently popular are all caused by known pathogens, and no new infectious diseases caused by new viruses or bacteria have been detected. It is necessary to give full play to the role of traditional Chinese medicine, integrate traditional Chinese and Western medicine, target common respiratory diseases in winter, popularize knowledge about the prevention and treatment of diseases with traditional Chinese medicine, and improve the effectiveness of prevention and treatment.
Zhendong Pharmaceutical (300158.SZ): The third phase of the employee stock ownership plan purchased a total of 2.61% of shares
Gelonghui Pharmaceutical (300158.SZ) announced on November 15, Zhendong Pharmaceutical (300158.SZ) announced that as of the disclosure date of this announcement, the third phase of the company's employee stock ownership plan has purchased a total of 26,768,900 shares of the company's shares through centralized bidding transactions through the secondary market, accounting for 2.6053% of the company's total share capital. The total transaction amount is 156,515,326 yuan, and the average transaction price is about 5.85 yuan/share.
Zhendong Pharmaceutical (300158.SZ): Net loss of 154.16,600 yuan in the third quarter
Glonghui, October 22丨Zhendong Pharmaceutical (300158.SZ) announced its report for the third quarter of 2023. Revenue for the reporting period was 851 million yuan, down 20.74% from the previous year; net profit attributable to shareholders of listed companies - 154.166 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 20.375,400 yuan; basic earnings per share - 0.0150 yuan/share.
Zhendong Pharmaceutical (300158.SZ): The company currently has no APIs for weight loss and treatment of mycoplasma pneumonia in children
Glonghui, October 17丨Zhendong Pharmaceutical (300158.SZ) said on the investor interactive platform that the company currently has no APIs to lose weight or treat mycoplasma pneumonia in children.
Zhendong Pharmaceutical: Does metformin have an effect on Alzheimer's disease? The company has not conducted relevant clinical trials, so it is impossible to reach a similar conclusion
Glonghui, October 17 | Zhendong Pharmaceutical said on an interactive platform that the company's subsidiary, Shanxi Zhendong Anxin Biopharmaceutical Co., Ltd. has production approval for metformin hydrochloride tablets. Its drug instructions show that metformin tablets are used in type II diabetics who are not satisfied with diet control alone, especially those who are obese and those with hyperinsulinemia. Using this drug not only lowers blood sugar, but may also have the effect of reducing weight and hyperinsulinemia. Please refer to the drug manual for details. Whether metformin has an effect on Alzheimer's disease, the company has not conducted relevant clinical trials, so it is impossible to reach a similar conclusion.
Zhendong Pharmaceutical (300158.SZ): The third phase of the employee stock ownership plan bought a total of 1.4777% of shares
Glonghui Pharmaceutical (300158.SZ) announced that as of the disclosure date of this announcement, the third phase of the company's employee shareholding plan has purchased a total of 15,182,900 shares of the company through centralized bidding transactions through the secondary market, accounting for 1.4777% of the company's total share capital. The total transaction amount is 88,079,844 yuan, with an average transaction price of about 5.80 yuan/share.
Analysis
Price Target
No Data
